© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
Presented by CURE®, a collection of resources that provide information and support for patients with squamous cell carcinoma and the professionals who treat them.
April 12th 2021, 1:00pm
Chronic immune-related adverse events from anti-PD-1 therapy occur in many patients with advanced melanoma, but shouldn’t deter them from seeking treatment that can provide long-term survival, according to an expert from Vanderbilt University Medical Center.
April 8th 2021, 6:00pm
An expert spoke with CURE® about the FDA’s recent approval of Libtayo to treat patients with locally advanced basal cell carcinoma who previously had only one therapy option for locally advanced disease.
March 19th 2021, 6:00pm
FDA approval of immunotherapies and BRAF/MEK inhibitors may have impacted overall survival, with a change from seven months between 2010 and 2014 to 13 months between 2015 and 2019.
March 8th 2021, 1:45pm
As the winter months stretch on, those looking to treat Seasonal Affective Disorder (SAD) may be tempted to use indoor ultraviolet (UV) tanning devices. Not only is indoor tanning a dangerous habit, it does not successfully treat SAD.
March 1st 2021, 10:00pm
A patient with recurrent basal cell carcinoma discusses his cancer journey, his latest challenge and how he’s now prioritized quality of life over quantity.
February 23rd 2021, 2:15pm
Intratumoral injection—the boosting of the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses—is a promising treatment method because it’s effective AND it seems to cause fewer toxicities for the patient than combination systemic immunotherapy.
February 16th 2021, 2:00pm
Gina Roller’s best friend, Kerri-Lynn Larimer, adopted and lived by the motto “crazy not to” long before she was diagnosed with metastatic melanoma.
February 9th 2021, 11:00pm
The Food and Drug Administration has granted an accelerated approval to Libtayo for the treatment of patients with advanced basal cell carcinoma, a type of skin cancer, who were previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI was not appropriate.
February 9th 2021, 2:00pm
We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment; and Medical Director, Cancer Center, California Pacific Medical Center.
February 2nd 2021, 3:06pm
We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain anonymous.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer